tbuckley/cabot-search huggingface dataset:
Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim)
Authors: L. E. Spitler, R. W. Weber, S. Cruickshank, T. L. Whiteside
Journal: Journal of Clinical Oncology (2009)

e20004 Background: Our previous study suggested that administration of GM-CSF to high-risk melanoma patients may prolong survival (JCO 18(8):1614–1621, 2000) and led to a prospective randomized trial (E4697). This study has completed accrual and follow-up is now ongoing. Simultaneously, we conducted a follow-on study to gain further information about the immunological effects and clinical outcomes of adjuvant GM-CSF therapy of melanoma. Methods: GM-CSF, 125 μg/m 2 , was administered subcutaneously in 28-day cycles of 14 days on/14 days off for 1 year. Blood draws were keyed to GM-CSF administration: Days 0 (before), 15 (after 14 days on GM-CSF), 29 (after 14 days off GM-CSF), 155 and 351 (after 14 days on GM-CSF in the 6th and 13th cycle). Forty- nine patients were evaluable for immunologic responses on Day 15. Immunophenotyping of the white cell population was done on a subset consisting of 6 patients. Results: In 42 patients, there was an increase in the WBC counts to above normal after 14 days of GM-CSF therapy in the first cycle. This increase did not occur in 7 patients and these patients had a significantly shorter survival. There was a similar increase in neopterin levels following 14 days of GM-CSF administration, which returned to baseline after 14 days off therapy and did not correlate with clinical outcome. Immunophenotypic analysis showed an increase in activated and regulatory T cells and a decrease in the percent of CD11c+DC (myeloid) cells in the 6 patients evaluated, all returning to baseline on Day 29. Conclusions: GM-CSF therapy was associated an increase in the WBC counts in the majority of patients after 14 days of treatment and patients who did not experience this increase had a significantly shorter life expectancy. The observed increase in neopterin levels is consistent with macrophage activation as the potential mechanism of action of adjuvant GM-CSF administration. Additional immunologic effects which may play a role during GM-CSF therapy include the increase in activated T-cells and decrease in CD11c+DC, which may be moving from the peripheral circulation into the tissues. [Table: see text]
Multicenter randomized phase II trial of cisplatin, irinotecan plus bevacizumab (PCA) versus docetaxel, cisplatin, irinotecan plus bevacizumab (TPCA) in patients (pts) with metastatic esophagogastric cancer (MEGCA).
Authors: Peter C. Enzinger, Eunice Lee Kwak, Jackie Szymonifka, Thomas Adam Abrams, Eileen Regan, Paige Malinowski, Kent C. Shih, Jill N. Allen, Nadine Jackson, Jennifer A. Chan, Panos Fidias, David P. Ryan, Charles S. Fuchs, Johanna C. Bendell
Journal: Journal of Clinical Oncology (2012)

4027 Background: In MEGCA, PCA has a 65% response rate (RR) and 8.3 mos time to progression (Shah. JCO 2006); TPCA has a 66% RR and 8.9 mos progression-free survival (PFS) (Enzinger. ESMO 2008 updated). Methods: Chemo naive pts with MEGCA were stratified: ECOG (0/1 vs. 2) and disease site (Gastric or GEJ/esophageal) and randomized 1:1 to PCA or TPCA. PCA -- cisplatin 30mg/m2 and irinotecan 65mg/m2 on d1, 8, and bevacizumab 10 mg/kg d1 docetaxel 30mg/m2, cisplatin 25mg/m2 and irinotecan 50mg/m2 on d1, 8, and bevacizumab 10 mg/kg d1. Cycles were 3 weeks. Response assessment - q6wks (RECIST 1.1). Primary endpoint was PFS. Results: 85 patients: median age=61 (40-85); male/female= 70/15; ECOG: 0/1/2=(34/49/2); gastric/GE junction/esophageal=27/21/37; measurable/evaluable: 78/7; sites of metastatic disease (# of pts): lymph nodes (34), liver (31), lung (11), bone (5), abdomen (4), peritoneum (4), other (11). There were two treatment-related deaths: esophageal hemorrhage, sudden death (both TPCA). Conclusions: Both regimens were efficacious and reasonably well tolerated. The addition of docetaxel to the attenuated PCA combination did not significantly improve efficacy. [Table: see text]
Acute promielocytic leukemia: 14 years experience at the University Hospital, San Juan, Puerto Rico
Authors: A. T. Lopez-Enriquez
Journal: Journal of Clinical Oncology (2009)

e18006 Background: Acute promielocytic leukemias (APL) are a unique example in carcinogenesis, of maturation arrest at the promielocytic stage, associated with a chromosomal reciprocal translocation of a portion of chromosome 15 and 17 with the formation of fusion proteins between the PML gene and the alpha-retinoic acid receptor site. Methods: Since 1994 when transretinoic acid (ATRA) became available to us, we developed a protocol incorporating this drug to the standard regime of induction chemotherapy for acute leukemias used in our institution of 7 days of continuous infusion of cytosine arabinoside (Ara-C) and three days of daunorubicine (7+3), starting the ATRA on day 14 at 45 mg/m2 and continued daily for 120 days. Two to three more courses of consolidation with high-dose Ara-C, Ara-C with daunorubicine or daunorubicine alone where given. Results: We have treated 91 patients with APL since 1994 up to November 2008. Eighty-nine (89) patients received 7+3+ATRA. Nineteen of eighty-nine (19/89) died early in the first two weeks of treatment mainly secondary to bleeding and sepsis for a 21% early death rate. Sixty-seven of seventy (67/70) patients went into complete remission for a 98% rate. Four patients developed ATRA syndrome; three early pulmonary syndromes with one death, and the other two responded to steroids and went into remission. A fourth developed increased intracranial pressure two weeks on ATRA, resolved on steroids, Diamox, and continued on a lower ATRA dose. Fifty-three (53) has remained in complete remission with a range of 6months to 14 years, for a rate of 76%. Seventeen (17) patients or 25% (17/70) relapsed within the first 2 years of treatment. Thirteen of 17 (13/17) relapsed after receiving Dauno x3 x3 as consolidation chemotherapy for a 76% relapsed rate. Conclusions: The initial high early mortality needs to be addressed with a more aggressive support system. A 98% complete remission rate for induction chemotherapy is extraordinary, no ATRA syndrome when started on day 14 of treatment, reducing further morbidity and mortality. Daunorubicine as a single agent in consolidation is inappropriate in our population. No significant financial relationships to disclose.
Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy.
Authors: Cristina Pirvulescu, Sibylle Loibl, Gunter Von Minckwitz, Christine Mau, Jens U. Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, Michael Untch
Journal: Journal of Clinical Oncology (2012)

541 Background: Patients (pts) with infiltrating lobular carcinoma (ILC) have a different response to neoadjuvant chemotherapy compared to patients with non-lobular carcinoma (NLC). The aim of our analysis was to characterize correlates of the outcome impact of neoadjuvant chemotherapy in ILC and to compare those with NLC. Methods: Between 1998 and 2006; 6377 breast cancer patients were enrolled to 7 randomized neoadjuvant chemotherapy trials in Germany. For 6205 (98.3%) pts the histological type was available. 844 (13.6%) were classified as ILC, 5361 (86.4%) were classified as NLC. Endpoints of the analyses were: pathological complete response (pCR) defined as no invasive and no in-situ residuals in the breast and the lymph nodes, type of surgery, disease-free (DFS), local recurrence (LRFS) and overall survival (OS). Results: ILC was associated with older age, larger tumor size, negative nodes, lower grading, and hormone receptor (HR) positivity (all p&lt;0.0001). The majority of pts with ILC were HR positive (717 pts, 86.9%) and had G1-G2 tumors (603 pts, 78.6%). Patients with ILC had a significant lower pCR rate than pts with NLC (pCR 6.04% vs. 16.4%, p&lt;0.001). In the ILC group, pts with HR positive, triple-negative and HER2-positive tumors had a pCR rate of 5%, 18.3% and 9.2%, respectively. One of 35 pts with G1 and HR positive ILC had a pCR. Breast conservation therapy (BCT) in pts with pCR was 72.5% in the ILC group and 85.5% in the NLC group (p&lt;0.0001). Predictors for pCR in the multivariate analysis were for ILC: patient age, grading and HR status. ILC pts had a significantly longer LRFS compared to NLC pts (with or without pCR after neoadjuvant chemotherapy, mean 112 months 95%CI [109.7-115.7] vs. 106 months 95%CI [104.4-107.4], p=0.002). Conclusions: In patients with ILC age, grading and HR status were predictive for pCR. Pts with ILC have a more favourable outcome after neoadjuvant chemotherapy despite a significantly lower pCR rate compared to pts with NLC.
Premature Platelet Activation and Resistance to P2Y12 Inhibitors in Rasa3 Mutant Mice
Authors: Wolfgang Bergmeier, David S Paul, Lucia Stefanini, Raymond F. Robledo, E. Ricky Chan, Todd M Getz, Raymond Piatt, Yacine Boulaftali, Mark D Adams, Luanne L. Peters
Journal: Blood (2014)
Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC)
Authors: K. Tauer, L. S. Schwartzberg, A. Epperson, B. V. Fortner
Journal: Journal of Clinical Oncology (2006)

10697 Background: Platinum compounds given with taxanes have emerged as an active combination for the treatment of MBC. However, optimal scheduling of these drugs is unknown. While evidence suggests weekly P may be superior to Q 3 wks, conflicting data exists for weekly vs. Q 3–4 wk C. Methods: Eligible patients (pts) had no prior chemotherapy for Stage IV disease and no prior exposure to platinum agents. Pts were stratified by HER2 status and randomized to receive either C, AUC 2, day 1,8,15 (C1 arm) + P 80 mg/m 2 day 1,8,15 or C, AUC 6 day 1 (C4 arm) + P 80 mg/m 2 day 1, 8, 15 in a 28 day cycle. HER2+ pts received T weekly at 2mg/kg after a loading dose of 4 mg/kg. The primary endpoint, overall response rate (ORR), was evaluated after every 2 cycles of therapy. Results: To date, 35 patients have been enrolled (19 HER2+). 31 are evaluable for toxicity and 22 for response. The median age is 52 (range 25–76), 17 had prior adjuvant therapy, median number of sites of disease was 2. Partial responses were noted in 4/10 in C4 arm and 7/12 in C1 arm for an ORR of 50%. The ORR for Her2+ pts to CP+T was 64%. 8/16 (50%) pts on the C4 arm and 2/15 (13.3%) pts on the C1 arm had grade 3/4 toxicity, predominantly hematological. Dose reductions occurred in 3 pts on C4 arm and 3 pts on C1 arm. Conclusions: Carboplatin and paclitaxel (± trastuzumab) is an active regimen when C is given in either weekly or Q 4 wk schedules. Hematologic toxicity is significantly less when C and P are both given weekly, and thus should become the preferred schedule in MBC. No significant financial relationships to disclose.
BIOMARKER PROFILE IN ADULTS WITH FONTAN CIRCULATION
Authors: Anita Saraf, Christine De Staercke, Fred Rodriguez, Andreas Kalogeropoulos, Andrea Knezevic, Jennifer Gerardin, Georges Ephrem, Salim Hayek, Staci Jennings, Agasha Katabarwa, Arshed Quyyumi, Wendy Book
Journal: Journal of the American College of Cardiology (2017)
Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study
Authors: Yael Cohen, Moshe E. Gatt, Noa Lavi, Chezi Ganzel, Hila Magen, Irit Avivi, Tamar Tadmor, Celia Suriu, Osnat Jarchowsky Dolberg, Amitai Papushado, Svetlana Trestman, Ron Ram
Journal: Blood (2016)
IMPACT OF GENDER DIFFERENCE IN CLINICAL PRESENTATION ON LONG-TERM OUTCOMES IN CHINESE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Xiao-Fang Tang, Ying Song, Jing-Jing Xu, Yuan-Liang Ma, Yi Yao, He Chen, Jia-Hui Zhang, Huan-Huan Wang, Ping Jiang, Lin Jiang, Liu Ru, Zhan Gao, Xue-Yan Zhao, Run-Lin Gao, Jin-Qing Yuan
Journal: Journal of the American College of Cardiology (2017)
Impact of racial residential segregation (RRS) on stage at diagnosis and survival after diffuse large B-cell lymphoma (DLBCL).
Authors: Loretta J. Nastoupil, Christopher Flowers, Daphne Lichtensztajn, Scarlett Lin Gomez, Jessica Williams, Christina A. Clarke, Theresa H.M. Keegan
Journal: Journal of Clinical Oncology (2015)

6557 Background: Racial disparities in disease presentation and survival have been reported for DLCBL, which may arise from biological or socioeconomic status (SES) differences that influence treatment and outcomes. We examined the associations between RRS, stage at diagnosis, overall survival (OS) and lymphoma-related survival (LRS) for non-Hispanic Black and White patients (pts), hypothesizing that RRS is associated with advanced stage disease and inferior survival for Black pts with DLBCL. Methods: We merged data from the population-based California Cancer Registry for new cases of DLBCL diagnosed during 1996-2007 with 5 Census indices of segregation among Blacks relative to Whites: dissimilarity, exposure, isolation, relative centralization, and spatial proximity. We included a measure of the % of black individuals per neighborhood (%B). Controlling for demographic and clinical factors, we used multivariable logistic regression and Cox regression to examine each RRS measure, modified by %B, on stage and survival, respectively, for Blacks and Whites separately. Results: Among 10,505 White and 749 Black DLBCL pts, Blacks more commonly had advanced stage disease (52 vs 45%) and resided in the lowest SES neighborhoods (28 vs 7%). Among Black pts, medium to high segregation as measured by dissimilarity (HR 2.1; 95% CI 1.1-4.1) and isolation (HR 2.2; 95% CI 1.0-5.0) were associated with advanced stage; however, there were no significant association between any RRS measure and survival. Among White pts, there was no significant associations between RRS and stage; whereas low segregation measured by spatial proximity (LRS HR 1.2; 95% CI 1.2-1.1; OS HR 1.2; 95% CI 1.1-1.4), isolation (LRS HR 1.3; 95% CI 1.1-1.5; OS HR 1.3; 95% CI 1.1-1.4), and dissimilarity (LRS HR 1.2; 95% CI 1.0-1.4; OS HR 1.3; 95% CI 1.1-1.4) in neighborhoods with high %B were associated with worse OS and LRS. Conclusions: Despite association with stage at diagnosis for Black pts, neighborhood composition and segregation had minimal impact for White pts and no impact for Black pts on survival, suggesting that other sociological/biological factors influence racial differences in DLBCL survival.
Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison.
Authors: Stefan Faderl, Nitin Jain, Susan Mary O'Brien, Deborah A. Thomas, Farhad Ravandi, Elias Jabbour, Sherry Pierce, Hagop M. Kantarjian
Journal: Journal of Clinical Oncology (2013)

7095 Background: Modern multi-agent chemotherapy (CT) regimens result in complete remission (CR) rates of 80-90% and long-term survival rates of 40% in pts with ALL. The most common reason for treatment failure is relapse of the disease. Post-relapse therapies lead to second CR in 30-40% of pts with a 5-year survival of &lt;10%. CD22 expression occurs in &gt;90% of pts with ALL. Inotuzumab ozogamicin (IO) is a CD22 monoclonal antibody bound to a toxin, calecheamicin. We reported overall response rate of 57% with single-agent IO in R/R ALL (Kantarjian, Lancet Oncology 2012). Methods: We analyzed the outcomes of patients with R/R ALL treated with single-agent IO (n=90) vs. historical controls (n=292) treated with combination CT at our institution from 1990-2008. IO was dosed at 1.8 mg/m2 every 3-4 weeks (first 41 pts), and later weekly dosing (0.8 mg/m2 day 1, 0.5 mg/m2 on days 8 and 15, every 3-4 weeks). Fifty-percent of historical controls were treated with hyper-CVAD CT (n=147). Results: The median age in the IO cohort was 39.5 years (yrs) (range 4-84) and in the CT cohort was 37 yrs (range 14-81). Overall CR/CRp rate was 49% with IO vs. 29% with CT. In salvage 1, CR/CRp rate was significantly better with IO [66% vs. 40% with CT (p=0.007)]. When only hyper-CVAD-based regimens were included, the CR/CRp was not statistically different (66% with IO vs. 56% with hyper-CVAD, p=0.332). In salvage 1, the median overall survival (OS) was 9.2 months (mos) with IO vs. 6.2 mos with CT (p=0.06 compared with IO) vs. 7.9 mos with hyper-CVAD (p=0.48 compared with IO). In salvage 2, CR/CRp rate was better with IO vs. CT (44% vs. 16%, p=&lt;0.001); OS was not different (4.3 mos vs. 2.5 mos, p=0.74). In salvage 3, CR/CRp rate was better with IO vs. CT (46% vs. 19%, p=0.03); OS was also better with IO vs. CT (6.6 mos vs. 2.6 mos, p=0.01). In salvage 4, CR/CRp rate was better with IO vs. CT (27% vs. 9%, p=0.01); OS was not statistically different (7.4 mos vs. 1.9 mos, p=0.09). Conclusions: In pts with R/R ALL, outcomes after single-agent IO are better than pts treated with CT alone. In addition, IO has fewer side effects than CT. IO has the potential to replace multi-agent CT as standard of care for treatment of pts with R/R ALL.
The ICM research agenda on intensive care unit-acquired weakness
Authors: Nicola Latronico, Margaret Herridge, Ramona O. Hopkins, Derek Angus, Nicholas Hart, Greet Hermans, Theodore Iwashyna, Yaseen Arabi, Giuseppe Citerio, E. Wesley Ely, Jesse Hall, Sangeeta Mehta, Kathleen Puntillo, Johannes Van den Hoeven, Hannah Wunsch, Deborah Cook, Claudia Dos Santos, Gordon Rubenfeld, Jean-Louis Vincent, Greet Van den Berghe, Elie Azoulay, Dale M. Needham
Journal: Intensive Care Medicine (2017)
Halofuginone Induces Post-Transcriptional Down-Regulation of Cyclin D1, Cell Cycle Arrest and Apoptosis In Mantle Cell Lymphoma Cells through Activation of Integrated Stress Response Pathways
Authors: Rodrigo Proto-Siqueira, Melina G. Santos, Valdemir M. Carvalho, Yumi H. Maekawa, Leonardo A. Testagrossa, Zelia R. Andrade, José Salvador Oliveira, Maria de Lourdes L. F. Chauffaille, Marco A. Zago, Arnon Nagler, Adrian Wiestner, Edgar Gil Rizzatti
Journal: Blood (2010)
SUBCLINICAL ATHEROSCLEROSIS, STATIN ELIGIBILITY, AND OUTCOMES IN AFRICAN AMERICANS: THE JACKSON HEART STUDY
Authors: Aferdita Spahillari, Stanford Mwasongwe, John Carr, James Terry, Robert Mentz, Daniel Addison, Udo Hoffmann, Jared Reis, Jane Freedman, Joao Lima, Adolfo Correa, Venkatesh Murthy, Ravi Shah
Journal: Journal of the American College of Cardiology (2017)
PARADOXICAL HYPERTENSIVE ADVERSE REACTION TO NITROGLYCERINE DURING TILT TABLE TEST UNMASKING UNDIAGNOSED PHEOCHROMOCYTOMA: A CASE REPORT
Authors: Amit Arbune, Sharad Malavade, Timothy Edmiston, Zulfiqar Baloch, Saurabh Chokshi
Journal: Journal of the American College of Cardiology (2017)
OUTCOMES OF THE HYBRID VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS) MAZE FOLLOWED BY CATHETER ABLATION IN PATIENTS WITH PERSISTENT AND LONGSTANDING PERSISTENT ATRIAL FIBRILLATION: CLINICAL RESULTS FROM A HIGH-VOLUME CENTER
Authors: Daniel Kaiser, Carrie Pierce, Shelby Burk, L. Bing Liem, Peter Chang Sing, Gansevoort Dunnington
Journal: Journal of the American College of Cardiology (2017)
PILOT TRIAL COMPARISON OF A KAOLIN-BASED HEMOSTATIC PAD (QUIKCLOT ® RADIAL™) VERSUS MECHANICAL COMPRESSION (TR BAND ® ) TO REDUCE COMPRESSION TIME FOLLOWING TRANSRADIAL ACCESS
Authors: Jonathan S. Roberts, Jianli Niu, Ann Robblee, Shu-Shanna Dixon, Dawn Nardiello, Ricardo Guedes, Juan Pastor-Cervantes
Journal: Journal of the American College of Cardiology (2017)
CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: INSIGHTS FROM PARADIGM-HF
Authors: Solmaz Ehteshami-Afshar, Nathaniel M. Hawkins, Jean Rouleau, Karl Swedberg, Michael Zile, Martin Lefkowitz, Victor Shi, Scott Solomon, Milton Packer, John McMurray
Journal: Journal of the American College of Cardiology (2017)
A COST-EFFECTIVE ANALYSIS OF SHORT DURATION DUAL ANTI-PLATELET THERAPY (DAPT) WITH A BIOABSORBABLE POLYMER STENT PLATFORM VERSUS LONGER DURATION DAPT WITH A DURABLE POLYMER DRUG-ELUTING STENT IN A PATIENT POPULATION UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Authors: Benjamin Zev Galper, Matthew Reynolds, Eric Secemsky, Pallav Garg, David Cohen, Robert Yeh
Journal: Journal of the American College of Cardiology (2017)
Maintenance Rituximab after Autologous Stem Cell Transplant for High-Risk B-Cell Lymphoma Induces Prolonged and Severe Hypogammaglobulinemia.
Authors: Seah H. Lim, Yana Zhang, Zhiqing Wang, William V. Esler, David Beggs, Brian Pruitt, Paul Hancock, Mary Townsend
Journal: Blood (2004)
Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC).
Authors: Tetsuya Mitsudomi, Yasuo Iwamoto, Kazuto Nishio, Takeharu Yamanaka, Hiroshige Yoshioka, Hirohito Tada, Masahiro Yoshimura, Ichiro Yoshino, Isamu Okamoto, Shunichi Sugawara, Shinzoh Kudoh, Nobuyuki Yamamoto, Mitsunori Ohta, Yukito Ichinose, Shinji Atagi, Morihito Okada, Hideo Saka, Nobuyuki Katakami, Kazuhiko Nakagawa, Yoichi Nakanishi
Journal: Journal of Clinical Oncology (2013)

7518 Background: We conducted a randomized phase II trial for patients with resected stage II-IIIA NSCLC comparing postoperative oral S-1 (80 mg/m2/day for consecutive 2 weeks q3w for 1 year) (S) (N=100) or cisplatin (CDDP) (60 mg/m2 day1) plus oral S-1, (80 mg/m2/day for 2 weeks) q3w for 4 cycles (PS)(N=100). We reported that the disease-free survival rate at 2 years (DFS@2) (95% confidence interval: CI), a primary endpoint, was 66 (55-74) % for S and 58 (48-67)% for PS. Here, we report the preliminary results of preplanned biomarker analysis, a co-primary endpoint, to identify molecules whose expression is significantly associated with patient outcome. Methods: cDNA extracted from macro-dissected formalin-fixed paraffin-embedded specimens were available for 197/200 patients. Thirty-one genes including those whose expressions have been potentially associated withCDDP (e.g. ERCC1, XRCC1, BRCA1, GSTpi, HMG1, TBP) or fluorouracil (FU) sensitivity (TS, DHFR, DPD, UMPS, UPP1) were measured by QGE analysis (MassArray, Sequenom, CA). Expression of each gene was dichotomized according to its median value of expression. Results: The only gene with interaction P&lt;0.05 after adjustment with sex, histology, age, stage was UMPS (uridine monophosphate synthase) (P=0.0348). UMPS catalyzes the conversion of fluoro UMP from 5FU and thus high UMPS expression is implicated to enhance 5FU effect. DFS@2 % (95% CI) for UMPS high/S, UMPS high/CS, UMPS low/S, UMPS low/CS were 69 (54-80), 53 (37-66), 64 (49-76), 61 (46-73)%, respectively. However, molecules such as ERCC1 and GSTpi whose expression have been previously associated with CDDP sensitivity did not emerge as predictive markers (P=0.7908, 0.6406, respectively). Conclusions: UMPS expression may define patient subset that would benefit from postoperative S-1 therapy. Clinical trial information: 000001658.
GLOBAL PLAQUE BURDEN BY CAROTID AND FEMORAL 3D VASCULAR ULTRASOUND: THE PESA (PROGRESSION AND EARLY DETECTION OF SUBCLINICAL ATHEROSCLEROSIS) STUDY
Authors: Beatriz Lopez-Melgar, Leticia Fernandez-Friera, Belen Oliva, Jose Manuel Garcia-Ruiz, Vicente Martinez de Vega, Agustin Mocoroa, Borja Ibañez, Javier Sanz, Antonio Fernandez-Ortiz, Valentin Fuster
Journal: Journal of the American College of Cardiology (2017)
Water fluoridation [2] (multiple letters)
Authors: G. Jones, P. Connett, S. L.M. Gibson, R. G. Gibson, P. J. Holloway, M. S. McDonagh, J. Kleijnen, T. C. Schmidt, K. Phipps, E. Orwoll, J. Mason, J. Cauley, Baldwin, D. Mac Auley
Journal: BMJ (2001)
Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL
Authors: Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer
Journal: Blood (2016)